US 10822337
TGF-β inhibitorC
granted A61PA61P11/00A61P13/00
Quick answer
US patent 10822337 (TGF-β inhibitorC) held by Rigel Pharmaceuticals, Inc. expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61P, A61P11/00, A61P13/00, A61P15/00, A61P17/00